Biotech Values

[DewDiligence]

ARGS -36% PM on failure of phase-2 HIV trial:

http://finance.yahoo.com/news/argos-therapeutics-provides-clinical-research-120000973.html

The company announced top-line results of its double-blind, placebo-controlled Phase 2b clinical trial of AGS-004 in patients chronically infected with HIV-1. The primary endpoint of the trial, which required a 1.1 Log lower median viral load (VL) after 12 weeks of interruption of antiretroviral therapy (ATI) in the treatment group versus the placebo group, was not achieved.

CC at 8:30am ET.